Related Experiment Video
Updated: Nov 8, 2025
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review
William M Oldham1, Anna R Hemnes2, Micheala A Aldred3
1Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Insights
This workshop focused on using pulmonary vascular disease omics data to advance understanding, prevention, and treatment. Key recommendations include developing analytic methods and coordinating national research efforts for pulmonary vascular disease.
Area of Science:
- Cardiovascular Research
- Genomics and Data Science
Background:
- Pulmonary vascular disease (PVD) research requires advanced data analysis.
- Omics data offers potential for novel insights into PVD.
Purpose of the Study:
- To identify knowledge gaps and research priorities in PVD omics.
- To align PVD research with National Heart, Lung, and Blood Institute (NHLBI) strategic goals.
Main Methods:
- A workshop convened experts in PVD, omics, and data analytics.
- Discussions focused on applying omics data to PVD understanding, prevention, and treatment.
Main Results:
- Identified opportunities for multiomic dataset analysis.
- Highlighted the need to link molecular pathways and phenotypes to clinical outcomes in PVD.
Conclusions:
- Recommended developing and validating analytic methods for omics data.
- Advocated for national coordination of biosamples and data, preclinical investigator consortia, and master clinical trial protocols for PVD.
Abstract:
The National Heart, Lung, and Blood Institute and the Cardiovascular Medical Research and Education Fund held a workshop on the application of pulmonary vascular disease omics data to the understanding, prevention, and treatment of pulmonary vascular disease. Experts in pulmonary vascular disease, omics, and data analytics met to identify knowledge gaps and formulate ideas for future research priorities in pulmonary vascular disease in line with National Heart, Lung, and Blood Institute Strategic Vision goals. The group identified opportunities to develop analytic approaches to multiomic datasets, to identify molecular pathways in pulmonary vascular disease pathobiology, and to link novel phenotypes to meaningful clinical outcomes. The committee suggested support for interdisciplinary research teams to develop and validate analytic methods, a national effort to coordinate biosamples and data, a consortium of preclinical investigators to expedite target evaluation and drug development, longitudinal assessment of molecular biomarkers in clinical trials, and a task force to develop a master clinical trials protocol for pulmonary vascular disease.
